SLC5A2 and type 2 diabetes mellitus: Ertugliflozin l-pyroglutamic acid (EGZ) (Fig. 1) is the fourth drug in the SGLT2 inhibitor class and was approved by the U.S. Food and Drug Administration (FDA) in December 2017 under the brand name Steglatro® for the treatment of T2D.